Repository logo
 
Publication

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024

2025-03-08Journal article Open access
Simple item page
datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
datacite.subject.sdg17:Parcerias para a Implementação dos Objetivos
dc.contributor.authorTamargo, Juan
dc.contributor.authorAgewall, Stefan
dc.contributor.authorAmbrosio, Giuseppe
dc.contributor.authorBorghi, Claudio
dc.contributor.authorCerbai, Elisabetta
dc.contributor.authorDan, Gheorghe A
dc.contributor.authorDrexel, Heinz
dc.contributor.authorFerdinandy, Péter
dc.contributor.authorGrove, Erik Lerkevang
dc.contributor.authorKlingenberg, Roland
dc.contributor.authorMorais, João
dc.contributor.authorParker, William
dc.contributor.authorRocca, Bianca
dc.contributor.authorSulzgruber, Patrick
dc.contributor.authorSemb, Anne Grete
dc.contributor.authorSossalla, Samuel
dc.contributor.authorKaski, Juan Carlos
dc.contributor.authorDobrev, Dobromir
dc.date.accessioned2025-10-02T15:00:40Z
dc.date.available2025-10-02T15:00:40Z
dc.date.issued2025-03-08
dc.descriptionThis article is being edited by Prof. Gregory Lip as a guest editor, since Stefan Agewall is the editor-in-chief of the EHJ-CVP.
dc.descriptionA correction has been published: European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 5, August 2025, Page 485, https://doi.org/10.1093/ehjcvp/pvaf046
dc.description.abstractDespite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVDs) remain limited, thus reflecting the need for more effective and safer pharmacological strategies. In this review, we summarize the most relevant studies in cardiovascular pharmacotherapy in 2024, including the approval of first-in-class drugs for the treatment of resistant hypertension and pulmonary arterial hypertension, label expansions for bempedoic acid and semaglutide, and the results of major randomized clinical trials (RCTs) that have met the pre-specified primary endpoints, thereby filling some gaps in knowledge and opening new perspectives in the management of CVD, and those RCTs whose results did not confirm the proposed research hypotheses. We also include a section on drug safety, where we describe the newest data on adverse reactions and drug–drug interactions that may complicate treatment and/or reduce drug adherence with the consequent decrease in drug effectiveness. Finally, we present the most important ongoing phase 2 and phase 3 clinical trials assessing the efficacy and safety of cardiovascular drugs for the prevention and treatment of CVD.eng
dc.description.sponsorshipThe Deutsche Forschungsgemeinschaft (Research Training Group 2989, project 517043330 to D.D.), the National Institutes of Health (R01HL136389, R01HL163277, R01HL131517, R01HL160992, R01HL165704, and R01HL164838 to D.D.), and the European Union (large-scale network project MAESTRIA No. 965286 to D.D.). P.F. was supported by the National Research, Development and Innovation Office of Hungary (Research Excellence Program TKP within the framework of the Therapeutic Development Thematic Program of the Semmelweis University; National Heart Laboratory (RRF-2.3.1-21-2022-00003).
dc.identifier.citationJuan Tamargo, Stefan Agewall, Giuseppe Ambrosio, Claudio Borghi, Elisabetta Cerbai, Gheorghe A Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Roland Klingenberg, Joao Morais, William Parker, Bianca Rocca, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Juan Carlos Kaski, Dobromir Dobrev, New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 292–317, https://doi.org/10.1093/ehjcvp/pvaf012
dc.identifier.doi10.1093/ehjcvp/pvaf012
dc.identifier.eissn2055-6845
dc.identifier.issn2055-6837
dc.identifier.urihttp://hdl.handle.net/10400.8/14195
dc.language.isoeng
dc.peerreviewedyes
dc.publisherOxford University Press
dc.relation.hasversionhttps://academic.oup.com/ehjcvp/article/11/3/292/8064771
dc.relation.ispartofEuropean Heart Journal - Cardiovascular Pharmacotherapy
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCardiovascular drugs
dc.subjectNew cardiovascular drugs
dc.subjectDrug combinations
dc.subjectDrug interactions and safety
dc.subjectCardiovascular pharmacotherapy
dc.subjectCardiovascular pharmacological strategies
dc.titleNew pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024eng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage317
oaire.citation.issue3
oaire.citation.startPage292
oaire.citation.titleEuropean Heart Journal - Cardiovascular Pharmacotherapy
oaire.citation.volume11
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameMorais
person.givenNameJoão
person.identifier.ciencia-id3614-652A-118E
person.identifier.orcid0000-0003-3406-2878
relation.isAuthorOfPublication3bc0f910-a460-461f-863a-1ca701ee597f
relation.isAuthorOfPublication.latestForDiscovery3bc0f910-a460-461f-863a-1ca701ee597f

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
New pharmacological agents and novel ca...lar pharmacotherapy strategies in 2024.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.32 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ciTechCare - Artigos
ESSLei - Artigos em revistas internacionais